CYP
Cynata Therapeutics Limited
🇦🇺 ASX
🧬 BIOTECHNOLOGY
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
-17.61%
Annual Growth
5 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
1
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Cynata Therapeutics Ltd. engages in the development and commercialization of therapeutic products. The firm is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells and a precursor cell, mesenchymoangioblast (MCA) to manufacture cell therapy products, including mesenchymal stem cells, on a commercial scale. Its lead product candidate, CYP-001, is under Phase I trial and developed for the treatment of steroid-resistant acute graft-versus-host disease (GvHD). Clinical trials of Cymerus products in osteoarthritis, which is under Phase III trial, and diabetic foot ulcers (DFU) are ongoing. In addition, the Company has demonstrated the utility of its Cymerus technology in preclinical models of various diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome and other.
📈 Performance
Price History
-55.68%
1M
1Y
10Y
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
0%
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$0.19
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in CYP
1
📊 Total Capital Earnings
$15K
🔃 Average investment frequency
18 weeks
💵 Average investment amount
$600
⏰ Last time a customer invested in CYP
21 days
CYP investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
100%
👶 Age of investors
18 - 25
26 - 34
35 - 90
100%
🙋 Legal gender of investors
Female
Male
100%
Pearlers who invest in CYP also invest in...
IVE.AX was created on 2001-08-14 by iShares. The fund's investment portfolio concentrates primarily on total market equity. The fund aims to provide investors with the performance of the MSCI EAFE Index, before fees and expenses. The index is designed to measure the performance of stocks from Europe, Australasia and the Far East and may include large- or mid-capitalisation companies.
🙌 Performance (5Yr p.a)
4.93%
📊 Share price
$120.60 AUD
🇺🇸 UNITED STATES
VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
12.12%
📊 Share price
$126.03 AUD
🌏 GLOBAL
🤖 TECHNOLOGY
⛳️ DIVERSIFIED
📈 HIGH PRICE GROWTH
A200.AX was created on 2018-05-07 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. A200.AX aims to track the performance of an index (before fees and expenses) comprising 200 of the largest companies by market capitalisation listed on the ASX.
🙌 Performance (5Yr p.a)
4.22%
📊 Share price
$138.20 AUD
💸 FINANCIALS
⛳️ DIVERSIFIED
🇦🇺 AUSTRALIA
IVV.AX was created on 2000-05-15 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.
🙌 Performance (5Yr p.a)
17.56%
📊 Share price
$55.75 AUD
📈 HIGH PRICE GROWTH
🇺🇸 UNITED STATES
DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars.
🙌 Performance (5Yr p.a)
10.08%
📊 Share price
$8.98 AUD
🇦🇺 EX AUSTRALIA
📈 HIGH PRICE GROWTH
🩺 HEALTH CARE
Want more shares? Try these...
Cycliq Group Ltd. engages in the manufacture of electronic safety accessories for cyclists. The company is headquartered in Subiaco, Western Australia. The company went IPO on 2007-11-21. The firm operates predominantly in the technology industry, manufacturing high-definition bike cameras and safety lights. The company has operations in Australia and China, with direct-to-consumer sales from the Company's Website and Amazon, and access to more than 6,000 retail points of presence through a network of regional distributors and retail partners in the United States, United Kingdom, European Union (EU) and Asia-Pacific. The firm provides various accessories, including Duo Mount, Saddle Rail Mount, Fly6 - Rear Pannier Mount Pack, Fly12 - Handlebar Mount, Universal Adapter Pack, Cycliq Security Tag Holder, Microphone Filters and Fly6 Gen 3 Silicone Case. The company also offers lumiere unisex reflective jackets. Its subsidiaries include Cycliq Products Pty Ltd and Cycliq Research and Development (HK) Ltd.
🙌 Performance (5Yr p.a)
-16.00%
📊 Share price
$0.00 AUD
🛍️ CONSUMER
Catalyst Metals Ltd. engages in the acquisition, exploration and development of mineral properties. The company is headquartered in Perth, Western Australia. The company went IPO on 2006-07-26. The firm owns the 40 kilometers (km) long Plutonic Gold Belt in Western Australia hosting the Plutonic gold mine and neighboring underexplored, high-grade resources. The Plutonic Gold Mine is located over 300 km northeast of Meekatharra in the mid-west region of Western Australia, at the northern end of the Eastern Gold Fields Province. The company also owns and operates the high-grade Henty Gold Mine in Tasmania, which lies within the 25 km Henty gold belt. The company also controls +75 km of strike length immediately north of the +22Moz Bendigo goldfield and home to high-grade, greenfield resources at Four Eagles. The company has interests in over 13 exploration licenses and two retention licenses along the Whitelaw and Tandarra Faults north of Bendigo and in other areas north of the Fosterville and Inglewood gold fields. Four Eagles Gold Project is situated along the Whitelaw Gold Corridor.
🙌 Performance (5Yr p.a)
3.25%
📊 Share price
$2.65 AUD
⛏️ MINING
Cyprium Metals Ltd. engages in the exploration of gold and copper deposits in Indonesia. The company is headquartered in Subiaco, Western Australia. The Company’s flagship property is the Nifty Copper Mine in Western Australia, which produces copper from both oxide and sulfide resources. The Nifty Copper Mine is located on the western edge of the Great Sandy Desert in the north-eastern Pilbara region of Western Australia, approximately 350 kilometers (km) southeast of Port Hedland. Its other assets include copper-focused properties in the Paterson and Murchison Provinces, including multiple defined resources. Its Maroochydore deposit is located in the north-eastern Pilbara region of Western Australia, approximately 85km southeast of Nifty. Paterson Exploration Project is located in the north-eastern Pilbara region of Western Australia and covers over 2,400 km2 land package. The Murchison Copper Gold Project, comprising the Cue and Nanadie Well Copper Projects, is in the eastern Murchison region of Western Australia, over 20km east of Cue and 75km southeast of Meekatharra.
🙌 Performance (5Yr p.a)
-16.74%
📊 Share price
$0.03 AUD
⛏️ MINING